FDA expands approval of AstraZeneca’s Koselugo

The Food and Drug Administration said it approved AstraZeneca’s (AZN) Koselugo for pediatric patients one year of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The FDA previously approved Koselugo for pediatric patients two years of age and older with NF1 who have symptomatic, inoperable plexiform neurofibromas.